Eosinophils and eosinophil-derived proteins in children with moderate asthma

M.O. Hoekstra*, H. Hovenga**, J. Gerritsen*, H.F. Kauffman**

ABSTRACT: Laboratory parameters can contribute to the diagnosis of asthma, which is often a difficult procedure in paediatric patients. The aim of this study was to investigate the value of eosinophil cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) in the diagnosis of paediatric asthma.

The number of eosinophils, serum ECP and EDN, and urinary EDN were determined in 22 children with stable, allergic asthma, aged 4–14 yrs, and in 17 age-matched healthy controls. Symptoms were monitored, the peak expiratory flow rate (PEFR) was recorded in the younger children, and lung function tests (forced expiratory volume in one second (FEV1) and the provocative concentration of histamine causing a 20% fall in FEV1 (PC20)) were performed in the older children. None of the asthmatic children had respiratory symptoms. PEFR was not significantly different in asthmatic children compared to controls. The FEV1% predicted was significantly lower compared to controls.

The number of eosinophils, serum ECP and EDN, and urinary EDN were significantly higher in asthmatic children compared with controls. After correction of serum ECP and EDN, and urinary EDN for the number of eosinophils, the differences between patients and controls disappeared. The nocturnal PEFR and the FEV1% predicted was significantly lower compared to controls.

The results suggest that serum and urinary concentration of eosinophil-derived proteins can be determined instead of the number of eosinophils to support the diagnosis of asthma in childhood. The urinary concentration of eosinophil-derived neurotoxin can be especially valuable in young children, because in this age group quantification of lung function cannot be performed and blood sampling can be difficult.

Asthma is a common disease of childhood. The diagnosis of asthma is based on the presence of well-described clinical signs and symptoms [1]. Laboratory tests, such as eosinophil count in peripheral blood, can be supportive in the diagnosis of asthma. The eosinophilic granulocyte is an important proinflammatory cell in the pathogenesis of asthma [2]. Several investigations have found an increased number of eosinophils in the peripheral blood of asthmatic patients compared to healthy controls [3–5]. During airway inflammation, eosinophils release proteins, such as eosinophilic cationic protein (ECP) and eosinophil-derived neurotoxin (EDN) (=eosinophil protein X (EPX)), which are toxic to respiratory epithelium [6]. An increase in serum ECP is found in asthmatic patients, and a relationship between serum ECP and both disease activity [4, 5] and lung function [5] in asthma has been reported. ECP is also elevated in patients with nocturnal asthma [7]. EDN/EPX is an eosinophil-derived ribonuclease [8, 9]. An increase of serum EDN/EPX has been reported in asthmatic patients [5]. EDN/EPX has been quantified in urine of healthy persons, but it has never been measured in the urine of asthmatic patients [10]. Since EDN/EPX is produced especially by eosinophils, we decided to measure EDN/EPX in the urine of asthmatic children and controls.

The aim of the present study was to determine serum and urine concentrations of eosinophil-derived proteins in children, and to examine whether the levels could be related to the diagnosis of asthma.

Methods

Subjects

A group of 22 children aged 4–14 yrs, having diagnosed allergic asthma (according to the American Thoracic Society (ATS) criteria [11]) with perennial symptoms, and 17 healthy controls participated in the study. They were recruited from the paediatric out-patient department and from general practitioners in Groningen. Allergy was defined as the presence of an increased total immunoglobulin E (IgE) (corrected for age) and at least one increased specific IgE against an inhalant allergen. Lung function at the onset of the study of all the patients showed bronchial hyperresponsiveness (defined as the presence of a provocative concentration of histamine causing a 20% fall in forced expiratory volume in one second (PC20) <8 mg·mL⁻¹). The patients did not use any maintenance treatment for at least 4 weeks prior to
the study. Children who used systemic corticosteroids on more than three occasions in the 6 months prior to the study were excluded.

Controls were recruited from schools in the city of Groningen and had no symptoms or signs of asthma or allergy. Their family histories were negative for asthma and allergy. Total IgE concentration was within the normal range for age, and specific IgE was negative for the panel of allergens. During lung function testing, there was no fall in forced expiratory volume in one second (FEV1) at the maximum histamine provocation dose of 16 mg·mL⁻¹. The characteristics of patients and controls are presented in table 1.

Study design

All participants visited the out-patient department (OPD) in the morning between 09:00 and 10:00 h. Morning urine, collected at home between 06:00 and 07:00 h, was sampled and stored at -20°C. A history was taken and physical examination was performed. Subsequently, blood samples were taken under fasting conditions, and in children >8 yrs lung function was performed. Children <8 yrs performed a peak flow registration in the morning and in the evening for 7 days following the visit to the out-patient department.

Symptom score

Respiratory symptoms, such as wheezing, cough, sputum production and dyspnoea were recorded in a diary record card during the first 7 days after the visit to the OPD.

Peak flow recording

Peak expiratory flow rate (PEFR) was measured at home each day in the morning and in the evening using a mini-Wright peak flow meter during the 7 days after the visit to the OPD. The PEFR was recorded as the best of 3 measurements. PEFR values from the first three days were regarded as practice and were, therefore, not included in the calculations. PEFR values from the last 4 days were used to calculate the individual mean PEFR. On one day of the last 4 days at 04:00 h, the nocturnal PEFR was determined by the patients. To compensate for age-related differences in PEFR, each individual PEFR was expressed as a percentage of the PEFR predicted for age before calculating the mean PEFR of patients and controls. Diurnal peak flow variation was calculated as the difference between evening and morning PEFR (ΔPEFRₑₑ) and as the difference between evening and night PEFR (ΔPEFRₑₙ). Lung function

Patients were asked to refrain from taking salbutamol during 12 h prior to the visit to the OPD. After measuring FEV1 and vital capacity (VC) (on a Lode water-sealed spirometer, The Netherlands) bronchial hyper-responsiveness was determined by histamine provocation test, as described previously [11]. Briefly, PC20 was measured by inhalation of histamine-diphosphate in doubling doses according to a standardized protocol. Each concentration of histamine was nebulized with a separate French dosimeter. Inhaled concentrations of histamine were doubled from 0.25 up to 16 mg·mL⁻¹ as a maximum. The effect of each dose was measured 3 min after administration. The PC20 was defined as the concentration of histamine causing a 20% fall in FEV1. The exact PC20 was assessed by linear interpolation of the last two points of the log concentration response curve.

Number of eosinophils

Peripheral ethylenediamine tetra-acetic acid (EDTA) treated blood was diluted 10 times and stained with an eosin-formalin solution, consisting of 2.5 mL formalin and 25 mL eosin 1% per 250 mL distilled water. Dilution was performed with a Finnpipette Diluter (Labsystems, Helsinki, Finland). In this way, erythrocytes were lysed and eosinophils were stained. Eosinophils were counted with a Neubauer counting chamber.

IgE concentration

Total IgE antibody concentration and specific IgE antibody concentration (for major inhaled allergens: house dust mite, grass pollen, tree pollen, dog dander and cat dander) were determined with the Immuno CAP Technique according to the protocol of the manufacturer (Pharmacia, Uppsala, Sweden). The range of IgE with this method was 2–2000 U·mL⁻¹. Values above 2,000 U·mL⁻¹ were further quantified by dilution.

Determination of ECP and EDN

After the blood sample was taken, it was allowed to clot for 1 h at room temperature. Subsequently, the tubes were centrifuged twice at 1,450×g, and the serum
was collected and stored at -20°C. Serum ECP and EDN and urinary EDN were determined by radioimmunoassay according to a previously described method [11] (Pharmacia, Uppsala, Sweden). The range of ECP was 0–200 µg·L⁻¹ and the range of EDN was 0–400 µg·L⁻¹. Values above the upper detection limits were further quantified after dilution. Urinary EDN concentration divided by creatinine concentration (urinary EDN/Cr) was calculated after determining the concentration of creatinine in morning urine.

**Data analysis**

Before calculations were made, all variables with a non-Gaussian shaped distribution (IgE, serum ECP and EDN, urinary EDN, and urinary EDN/Cr) were log-transformed in order to obtain a Gaussian shaped distribution. Subsequently, comparison of mean values was performed using the Student’s t-test, with the exception of ECP. The variables with a Gaussian shaped distribution (PEF values, FEV1 % pred, and the number of eosinophils) are shown as the geometric mean ± SEM. All variables with a non-Gaussian distribution (IgE, serum ECP and EDN, urinary EDN, and urinary EDN/Cr) are shown as geometric mean and interquartile ranges (25% and 75%), with the exception of ECP. Because two controls had a negative log ECP value (ECP between 0 and 1), the mean ECP value in controls could not be calculated after log-transformation of ECP values. As a consequence, mean ECP values in patients and controls were compared with Mann Whitney U-test, and ECP values are shown as median ± interquartile range. A p-value less then 0.01 was considered to denote statistical significance. This p-value was chosen instead of the usual value of 0.05 to take into account the fact that multiple comparisons were made. Correlation between variables was performed with Pearson’s correlation test. All analyses were performed with the Statistical Package for the Social Sciences (SPSS)/ PC+ package.

**Informed consent**

The study was approved by the Medical Ethics Committee of the University Hospital of Groningen. The patients and their parents gave informed consent.

**Results**

**Symptom score**

All the patients were in a stable phase of their asthma and reported no symptoms of cough, wheezing or dyspnoea at the time of the study and in the following week.

**Peak flow recording (PEFR)**

Although PEFR values were lower and changes in PEFR were higher in patients than in controls, these differences did not reach statistical significance (table 1).

**Lung function**

FEV1 was significantly lower in patients (84±3% pred) than in controls (107±3% pred), as was FEV1/VC (shown as the ratio of FEV1 and VC multiplied by 100%) (77±3% in patients/89±2% in controls) (table 1).

**Number of eosinophils, serum ECP and EDN, urinary EDN and urinary EDN/Cr**

The number of eosinophils was significantly higher in patients (872±122 cells·µL⁻¹) than in controls (308±62 cells·µL⁻¹). Serum ECP and EDN, urinary EDN, and urinary EDN/Cr were also significantly higher in the patients than in the controls (table 2 and fig. 1).

**Table 2. – Laboratory parameters**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Patients</th>
<th>Controls</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eosinophil count* cells·mL⁻¹</td>
<td>872±122</td>
<td>308±62</td>
<td>0.001</td>
</tr>
<tr>
<td>Serum ECP* µg·L⁻¹</td>
<td>9.45 (6.2–12.7)</td>
<td>2.9 (1.2–5.9)</td>
<td>0.005</td>
</tr>
<tr>
<td>Serum EDN* µg·L⁻¹</td>
<td>31.8 (23.3–40.7)</td>
<td>15.4 (10.3–23)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>EDNµ µg·L⁻¹</td>
<td>1148 (610–2692)</td>
<td>585 (438–782)</td>
<td>0.01</td>
</tr>
<tr>
<td>EDNu/Crµ µg·L⁻¹</td>
<td>162 (91–20)</td>
<td>55 (34–79)</td>
<td>&lt;0.005</td>
</tr>
</tbody>
</table>

*: geometric mean±SEM; #: median and interquartile range (25–75%); Cr: creatinine. ECP: eosinophil cationic protein; EDN: eosinophil-derived neurotoxin; EDNu: urinary EDN.

**Fig. 1. – Serum ECP, serum EDN, and urinary EDN, concentrations. Patients are indicated by circles and controls are indicated by triangles. The geometric means were equal to the median values and are indicated by horizontal bars. One outlying value is indicated at the top of the figure in parenthesis by its actual value. ECP: eosinophil cationic protein; EDN: eosinophil-derived neurotoxin. +: p<0.005; **: p<0.01; ***: p<0.001.**
Correlation between laboratory parameters and lung function parameters

The morning and evening PEFR and ∆PEFR values were not significantly related to any of the laboratory parameters. The nocturnal PEFR was inversely related to urinary EDN/Cr (r=-0.77; p<0.001). The relationship between the nocturnal PEFR and urinary EDN was of borderline significance (r=-0.65; p<0.03). FEV1 % pred was inversely related to the eosinophil count (r=-0.65; p<0.01) (fig. 2), to urinary EDN (r=-0.65; p<0.01) (fig. 3) and to urinary EDN/Cr (r=-0.64; p<0.01). PC20 was not related to the eosinophil count, serum ECP or EDN, urinary EDN or urinary EDN/Cr in the group of asthmatic children.

Discussion

We found that serum concentration of ECP and EDN and the urinary concentration of EDN were significantly higher in children with atopic asthma than in healthy controls. A significant relationship was found between FEV1 and both the number of eosinophils in peripheral blood and the concentration of eosinophil-derived proteins in urine.

Other investigators have reported on the number of eosinophils and the serum concentration of eosinophil-derived proteins in asthmatic adults [12–18], and in asthmatic children [4, 5, 18, 19]. A comparison of the number of eosinophils and the concentration of eosinophil-derived proteins between asthmatic children and healthy controls was described previously [4, 5]. Our results are in accordance with the observations that the number of eosinophils [4, 5], ECP [4, 5] and serum EDN [5] are significantly higher in children with asthma than in controls. In both previous studies [4, 5], the concentration of ECP in the asthmatic children was higher than found in the present study. This might be due to differences in patient characteristics, as our patients suffered from relatively mild and stable asthma. The difference in ECP in asthmatic children reported in some studies might also be attributable to a difference in technique of blood sample handling. It has been shown that differences in time and temperature of storage of blood samples in the laboratory may influence the quantity of serum ECP generated [20].

An important difference between the present study and the previous studies [4, 5], is that we made a correction of the concentration of eosinophil-derived proteins for the number of eosinophils. This calculation seems to be justified, since eosinophils are the only cells in the body that produce these proteins. This correction was made in order to calculate the contribution of the number of eosinophils to the concentration of these proteins. After correction, it was found that the difference in eosinophil-derived proteins between asthmatic children and controls disappeared. This result indicates that the number of eosinophils in circulation is reflected in the serum and urinary concentrations of eosinophil-derived proteins. Thus, serum ECP, serum EDN and urinary EDN are not of additional value in discriminating children with and without asthma. This conclusion is in accordance with previously published data [4, 5].

This is the first study of urinary concentrations of EDN in asthmatic children, based on a method of determination described previously [8]. Urinary EDN was significantly higher in asthmatic children than in controls, although an overlap was observed. This overlap in values may be explained by the presence of different types of ribonucleases that have been identified in human urine. It cannot be excluded that the EDN assay used in this study cross-reacts with several ribonucleases. However, it was also found that urinary EDN was significantly related to nocturnal PEFR and to FEV1, which suggests that the difference in urinary EDN between patients and controls is associated with asthma. It is remarkable that a significant relationship was found between lung function and urinary EDN, but not with the serum parameters. This may be explained by the fact that serum ECP and EDN and urinary EDN reflect...
eosinophils in a different way. Since morning urine is collected over several hours, the concentration of EDN in morning urine represents an integration of EDN levels during several hours, whereas serum ECP and serum EDN reflect values at only one time-point. Thus, urinary EDN reflects eosinophil number over a period of time, compared with serum ECP and EDN, which reflect eosinophil numbers at a particular moment. As the release and apoptosis of eosinophils and the degradation of the cell is a dynamic process, it can be imagined that urinary EDN is a more complete reflection of the eosinophil cell than serum ECP or EDN. The present findings suggest that the determination of urinary EDN could be a simple and less invasive alternative to the determination of blood eosinophils when the diagnosis of childhood asthma is considered. In young children, in particular, this can be a useful parameter, since blood sampling in young children can be difficult.

It is not yet clear whether eosinophil-derived proteins are increased due to atopy rather than to asthma, or whether they are elevated in other disorders characterized by eosinophilic inflammation. Another issue for future study is the value of serum and urinary eosinophil-derived proteins in monitoring asthma, for which longitudinal clinical trials have to be performed.

In conclusion, our results suggest that the determination of the serum and urine concentrations of eosinophil-derived proteins can be determined instead of the number of eosinophils to diagnose asthma in children. The urinary concentration of eosinophil-derived neurotoxin might be an important additional and noninvasive tool in asthmatic children. Before definitive conclusions can be drawn on the value of eosinophil cationic protein and eosinophil-derived neurotoxin with respect to the diagnosis of childhood asthma, additional studies have to be carried out.

Acknowledgements: The authors thank Pharmacia BV (Woerden, The Netherlands) for the generous supply of ECP and EDN assays. They also thank A.E.J. Dubois, for critically reviewing this manuscript.

References